TG Therapeutics Inc TGTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance
TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update
TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026
TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026
TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis
TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026
Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm
TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Trading Information
- Previous Close Price
- $63.38
- Day Range
- $62.00–68.03
- 52-Week Range
- $26.76–68.03
- Bid/Ask
- $64.44 / $65.00
- Shares Outstanding
- 151.15M
- Market Cap
- $9.84B
- Volume/Avg
- 6M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 23.46
- Price/Sales
- 11.32
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 2.06%
Company Profile
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 399
Valuation
Metric | TGTX |
|---|---|
Price/Earnings (Normalized) | 23.46 |
Price/Book Value | 16.98 |
Price/Sales | 11.32 |
Price/Cash Flow | 41.57 |
Price/Earnings
TGTX
Financial Strength
Metric | TGTX |
|---|---|
Quick Ratio | 3.54 |
Current Ratio | 4.50 |
Interest Coverage | 4.21 |
Quick Ratio
TGTX
Profitability
Metric | TGTX |
|---|---|
Return on Assets (Normalized) | 12.73% |
Return on Equity (Normalized) | 28.93% |
Return on Invested Capital (Normalized) | 17.93% |
Return on Assets
TGTX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|fYhw@N# | LOCK|$!thR | $139B | |||
| Moderna Inc MRNA | LOCK|k#>YFzN | LOCK|&< | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|#Rx%r!l | LOCK|yv#z! | $95B | |||
| argenx SE ADR ARGX | LOCK|dTHwbb? | LOCK|Z!l | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|L^<p^v$ | LOCK|%N | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|W^K^rkbs | LOCK|@^&! | $31B | |||
| Incyte Corp INCY | LOCK|p#Yk>R& | LOCK|h?V | $25B | |||
| BioNTech SE ADR BNTX | LOCK|?p@Krq | LOCK|^YW | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|l^n#?R^ | LOCK|<SDf | $20B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|%$hM#C | LOCK|HcQ | $16B |
United States